Nanoparticles for the potential treatment of Alzheimer’s disease: A physiopathological approach

Abstract Alzheimer’s disease (AD) is a multifactorial neurodegenerative central system with high prevalence among the elderly and most common form of dementia. Oxidative stress crucial on AD pathogenesis leads to deposition neurofibrillary tangles Aβ plaques; therefore, use natural antioxidants or ROS scavengers could help avoid formation these aggregates. Similarly, Aβ-degrading/anti-aggregating molecules arrest progression. Otherwise, traditional anti-Alzheimer drugs such as acetylcholinesterase inhibitors improve memory attention deficits. Nevertheless, all are extensively metabolized, have low plasma concentration, cannot cross blood–brain barrier freely. This review discusses different strategies for nanocarrier conjugation brain targeting delivery, new approaches treatment according accepted hypotheses pathogenesis. Although none existent compounds can completely disease’s progression, development delaying initial late stages neurodegeneration. The discovery more complex nanosystems multiple in needed will be next step near future.